Pharmacological profile of once-weekly injectable semaglutide for chronic weight management

References

• Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts. 2019;12(2):131–136.
   Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. Can Med Assoc J. 192(31): E875–E891. 2020.
   Google Scholar
• World Health Organization. Obesity and Overweight 2021. Last accessed 2022 Mar 24. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• Obes Res. National Institutes of Health. 1998.
   Google Scholar
• Stephenson J, Smith CM, Kearns B, et al. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21(1):1990.
   Google Scholar
• Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modeling study. Lancet Diabetes Endocrinol. 2015;3(2):114–122.
   Google Scholar
• de Cosio Fg, Diaz-Apodaca B, Baker A, et al. US obesity mortality trends and associated noncommunicable diseases contributing conditions among white, black, and hispanic individuals by age from 1999 to 2017. SN Compreh Clin Med. 2021;3(6):1334–1343.
   Google Scholar
• Yang J, Hu J, Zhu C. Obesity aggravates COVID‐19: a systematic review and meta‐analysis. J Med Virol. 2021;93(1):257–261.
   Google Scholar
• Sanchis-Gomar F, Lavie CJ, Mehra MR, et al. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clinic Proc. 2020;95(7):1445–1453.
   Google Scholar
• OECD. The heavy burden of obesity. 2019. Available at: https://www.oecd.org/health/the-heavy-burden-of-obesity-67450d67-en.htm. Last accessed 2022 Mar 24.
   Google Scholar
• Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
   Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020(360):1–8.
   Google Scholar
• Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the National ACTION Study. Obesity. 2018;26(1):61–69.
   Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
   Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(3):1–203.
   Google Scholar
• Peirson L, Douketis J, Ciliska D, et al. Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. CMAJ Open. 2014;2(4):E306–E317.
   Google Scholar
• Barte JCM, Veldwijk J, Teixeira PJ, et al. Differences in weight loss across different BMI classes: a meta-analysis of the effects of interventions with diet and exercise. Int J Behav Med. 2014;21(5):784–793.
   Google Scholar
• Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open. 2019;9(8):e029966.
   Google Scholar
• Varkevisser RDM, van Stralen MM, Kroeze W, et al. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019;20(2):171–211.
   Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
   Google Scholar
• Research Group LAHEAD. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014;22(1):5–13.
   Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–38. 2013.
   Google Scholar
• World Health Organization. World Health Organization obesity: preventing and managing the global epidemic. Report of a WHO consultation WHO Technical Report Series. 2000;894.
   Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930.
   Google Scholar
• Tahrani A, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. Obesity. 2022;30(4):802–840. (In Press).
   Google Scholar
• Gasoyan H, Tajeu G, Halpern MT, et al. Reasons for underutilization of bariatric surgery: the role of insurance benefit design. Surg Obes Relat Dis. 2019;15(1):146–151.
   Google Scholar
• Love KM, Mehaffey JH, Safavian D, et al. Bariatric surgery insurance requirements independently predict surgery dropout. Surg Obes Relat Dis. 2017;13(5):871–876.
   Google Scholar
• Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen’s model of health services use. Surg Obes Relat Dis. 2018;14(3):404–412.
   Google Scholar
• González-Muniesa P, Mártinez-González M-A, Hu FB, et al. Obesity. Nat Rev Dis Primers. 2017;3(1):17034.
   Google Scholar
• Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64(11):1376–1385.
   Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
   Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analog semaglutide. J Med Chem. 2015;58(18):7370–7380.
   Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
   Google Scholar
• Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220–224.
   Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266.
   Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354.
   Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
   Google Scholar
• Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6). DOI:10.1172/jci.insight.133429.
   Google Scholar
• Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762.
   Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649.
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 384(11): 989–1002. 2021.
   Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 397(10278): 971–984. 2021.
   Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 325(14): 1403–1413. 2021.
   Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 325(14): 1414–1425. 2021.
   Google Scholar
• Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 10(3): 193–206. 2022.
   Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 327(2): 138–150. 2022.
   Google Scholar
• W Tea G. 2021. Two-year effect of semaglutide 2.4 mg vs. placebo in adults with overweight or obesity (STEP 5). Presented at the 39th annual meeting of The Obesity Society (TOS) held at ObesityWeek, Dallas, TX (Texas), Nov 1-5.
   Google Scholar
• Zhong P, Zeng H, Huang M, et al. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022;75(3):718–724.
   Google Scholar
• Lau DCW, Teoh H. Current and emerging pharmacotherapies for weight management in prediabetes and diabetes. Can J Diabetes. 2015;39:S134–S141.
   Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   Google Scholar
• Nreu B, Dicembrini I, Tinti F, et al. Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: an updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;161:108087.
   Google Scholar
• Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347–1352.
   Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730.
   Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
   Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated co-morbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.
   Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
   Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434.
   Google Scholar
• Moon S, Lee J, Chung HS, et al. Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials. Endocrinol Metab. 2021;36(3):647–660.
   Google Scholar
• Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399(10321):259–269.
   Google Scholar
• Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172.
   Google Scholar
• Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736–1748.
   Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515.
   Google Scholar
• Sánchez-Garrido MA, Brandt SJ, Clemmensen C, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851–1861.
   Google Scholar
• Hope DCD, Vincent ML, Tan TMM. Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity. Front Endocrinol. 2021;12:735019.
   Google Scholar
• Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 2022;34(1):59–74.e10.
   Google Scholar
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2021;134(1):14–19.
   Google Scholar
• Rybelsus (semaglutide) prescribing information. Novo Nordisk A/S. 2021.
   Google Scholar
• American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Suppl 1):S113–S124. 8.
   Google Scholar
• Viljoen A, Hoxer CS, Johansen P, et al. Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2019;21(3):611.
   Google Scholar
• Wilkinson L, Hunt B, Johansen P, et al. Cost of achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide versus dulaglutide in the United States. Diabetes Therapy. 2018;9(3):951–961.
   Google Scholar
• Lee M, Lauren BN, Zhan T, et al. The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2020;6(2):162–170.
   Google Scholar
• Lepsen EW, Zhang J, Thomsen HS, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 2018;28(1):23–32.e3.
   Google Scholar
• Newsome MB, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonlcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124.
   Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73.
   Google Scholar
• Zhang S, Manne S, Lin J, et al. Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States. Obes Sci Pract. 2016;2(2):104–114.
   Google Scholar
• Curfman GD, Morrissey S, Drazen JM. Sibutramine — another Flawed Diet Pill. N Engl J Med. 2010;363(10):972–974.
   Google Scholar
• Mahase E. Weight loss pill praised as “holy grail” is withdrawn from US market over cancer link. BMJ. 2020;368:m705.
   Google Scholar
• Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Can J Diabetes. 2020;44(7):575–591.
   Google Scholar
• American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Suppl 1):S125–S143. 9.
   Google Scholar
• Chumakova-Orin M, Vanetta C, Moris DP, et al. Diabetes remission after bariatric surgery. World J Diabetes. 2021;12(7):1093–1101.
   Google Scholar
• Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diab Endocrinol. 2019;7(5):344–355.
   Google Scholar